# A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

> **NCT07069712** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 100 (estimated)

## Conditions studied

- Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** AZD0901
- **DRUG:** Rilvegostomig
- **DRUG:** Trastuzumab Deruxtecan (T-DXd)
- **DRUG:** Capecitabine
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** FLOT Chemotherapy

## Key facts

- **NCT ID:** NCT07069712
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-17
- **Primary completion:** 2027-01-28
- **Final completion:** 2028-09-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07069712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07069712, "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07069712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*